Associations between plasma markers and symptoms of anxiety and depression in patients with breast cancer

• Published in: BMC psychiatry 2024-10, Vol.24 (1), p.678-15, Article 678
• Main Authors: He, Yibo, Cheng, Shangping, Yang, Lingrong, Ding, Lingyu, Chen, Yidan, Lu, Jing, Zheng, Ruzhen
• Format: Article
• Language: English
• Subjects: Adult; Amino acids; Anxiety; Anxiety - blood; Anxiety - diagnosis; Anxiety - psychology; Biomarkers; Biomarkers - blood; Breast cancer; Breast Neoplasms - blood; Breast Neoplasms - complications; Breast Neoplasms - psychology; Cancer patients; Case-Control Studies; Cell growth; Complications and side effects; Depression - blood; Depression - diagnosis; Depression, Mental; Development and progression; Diagnosis; Discriminant analysis; Enzyme-linked immunosorbent assay; Enzymes; Female; Glial fibrillary acidic protein; Glial Fibrillary Acidic Protein - blood; Glycoproteins; Health aspects; Humans; Intermediate filament proteins; Lactic acid; Lactic Acid - blood; Lipocalin; Lipocalin-2 - blood; Measurement; Medical diagnosis; Medical research; Medicine, Experimental; Mental depression; Mental disorders; Mental health; Metabolism; Middle Aged; Mood; Neurophysiology; Neutrophils; Patients; Physiological aspects; Plasma; Plasma levels; Prognosis; Proteins; Psychiatric Status Rating Scales; Psychological aspects; Risk factors; Solid tumors; Tomography; Tumors; Womens health
• ISSN: 1471-244X; 1471-244X
• DOI: 10.1186/s12888-024-06143-x

Among patients with solid tumors, those with breast cancer (BC) experience the most severe psychological issues, exhibiting a high global prevalence of depression that negatively impacts prognosis. Depression can be easily missed, and clinical markers for its diagnosis are lacking. Therefore, this study in order to investigate the diagnostic markers for BC patients with depression and anxiety and explore the specific changes of metabolism. Thirty-eight BC patients and thirty-six matched healthy controls were included in the study. The anxiety and depression symptoms of the participants were evaluated by the 17-item Hamilton Depression Scale (HAMD-17) and Hamilton Anxiety Scale (HAMA). Plasma levels of glial fibrillary acidic protein (GFAP) and lipocalin-2 (LCN2) were evaluated using enzyme linked immunosorbent assay, and plasma lactate levels and metabolic characteristics were analyzed. This study revealed that GFAP and LCN2 may be good diagnostic markers for anxiety or depression in patients with BC and that plasma lactate levels are also a good diagnostic marker for anxiety. In addition, specific changes in metabolism in patients with BC were preliminarily explored.